Industry Archives - Page 3 of 19 - EverGlade

Industry

MCDC RFI mNGS Solutions

MCDC Seeks Portable mNGS Solutions for Rapid Pathogen Detection

Leave a Comment / All Posts, CPE CBRND, Defense, Life Sciences / By

MCDC-RFI-Agnostic-Metagenomic-Next-Generation-Sequencing-for-Clinical-Diagnostics Overview of Solicitation The Medical CBRN Defense Consortium (MCDC), managed by Advanced Technology International (ATI) in support of the Capability Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (CPE CBRND), has released a Request for Information (RFI) titled Agnostic Metagenomic Next-Generation Sequencing (mNGS) for Clinical Diagnostics. Unlike traditional targeted assays, which require […]

MCDC Seeks Portable mNGS Solutions for Rapid Pathogen Detection Read More »

MCDC RFI Host-Based Diagnostics

MCDC’s Host-Based Diagnostics for Acute Infections RFI

Leave a Comment / All Posts, CPE CBRND, Defense, Life Sciences / By

MCDC Request for Information HOST-BASED DIAGNOSTICS Final A Shift Toward Host-Response Diagnostics The Medical CBRN Defense Consortium (MCDC), managed by Advanced Technology International (ATI), has released a Request for Information (RFI) titled Host-Based Diagnostics for Acute Infections. Issued in support of the Capability Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (CPE CBRND),

MCDC’s Host-Based Diagnostics for Acute Infections RFI Read More »

BARDA-BAA-advanced-medical-countermeasures

BARDA’s Modernized BAA: A New On-Ramp for Advanced Medical Countermeasure Development

Leave a Comment / All Posts, BARDA, Life Sciences / By

BARDA_FY23 Modernized BAA Solicitation – Amendment 7 The Biomedical Advanced Research and Development Authority (BARDA) has released its modernized Broad Agency Announcement (BAA-23-100-SOL-00004, Amendment 7), creating a flexible, multi-year pathway for industry to partner with the U.S. Government on advanced medical countermeasures (MCMs) for CBRN, pandemic influenza, and emerging infectious disease threats to the U.S.

BARDA’s Modernized BAA: A New On-Ramp for Advanced Medical Countermeasure Development Read More »

BARDA RFI Neuromuscular Junction

BARDA’s RRPV RFI on NMJ Micro-Physiological Systems for BoNT Evaluation

Leave a Comment / All Posts, BARDA, Life Sciences / By

RRPV_RFI_BoNT-NMJ RFI Final Post Overview of Solicitation The Rapid Response Partnership Vehicle (RRPV), on behalf of the Biomedical Advanced Research and Development Authority (BARDA), has released a Request for Information (RFI) focused on neuromuscular junction (NMJ) micro-physiological systems (MPS) for botulinum neurotoxin (BoNT) applications. Managed by Advanced Technology International (ATI), this RFI seeks to assess

BARDA’s RRPV RFI on NMJ Micro-Physiological Systems for BoNT Evaluation Read More »

BARDA RRPV RAPID Solicitation Rapid Antibody Production

BARDA’s RRPV 26-10-RAPID Solicitation for Rapid Antibody Production

Leave a Comment / All Posts, BARDA, Life Sciences / By

RRPV-26-10-RAPID The Biomedical Advanced Research and Development Authority (BARDA), through the Rapid Response Partnership Vehicle (RRPV), has released a new Request for Project Proposals (RPP) to stand up U.S.-based rapid antibody and protein binder production platforms that can go from pathogen gene sequence to immunoassay-ready reagents within weeks instead of months. This is a targeted opportunity to position platform

BARDA’s RRPV 26-10-RAPID Solicitation for Rapid Antibody Production Read More »

DARPA Hemorrhage Countermeasures RFI

DARPA Hemorrhage Countermeasures RFI

Leave a Comment / All Posts, DARPA, Emerging Technologies / By

DARPA-SN-26-61 Overview of Solicitation Hemorrhage remains one of the leading causes of preventable death on the battlefield, with existing countermeasures often falling short in their transition from laboratory research to clinical and commercial application. In response, the Defense Advanced Research Projects Agency (DARPA) Biological Technologies Office (BTO) has released a Request for Information (RFI) under

DARPA Hemorrhage Countermeasures RFI Read More »

BARDA RFI ARDS Prevention

BARDA RFI on Host-Directed Therapeutics for ARDS Prevention

Leave a Comment / BARDA, Life Sciences / By

Overview of Solicitation The Biomedical Advanced Research and Development Authority (BARDA), within the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services, has released a Request for Information (RFI)/Sources Sought Notice (SSN) titled “Host Directed Therapeutics for the Prevention of Progression to ARDS.” This effort, in support of BARDA’s

BARDA RFI on Host-Directed Therapeutics for ARDS Prevention Read More »

ARPA-H STOMP Program

ARPA-H STOMP Program: Advancing the Science of Microplastics and Human Health

Leave a Comment / All Posts, ARPA-H, Life Sciences / By

STOMP_ISO_ARPA-H-SOL-26-152 The Advanced Research Projects Agency for Health (ARPA-H) has released an Innovative Solutions Opening (ISO) for the Systematic Targeting of Microplastics (STOMP) program, signaling a major federal investment in understanding and addressing the health impacts of micro- and nano-plastics (MNPs). As mounting evidence links MNP exposure to a range of adverse health outcomes, ARPA-H

ARPA-H STOMP Program: Advancing the Science of Microplastics and Human Health Read More »

DARPA Eris

DARPA’s ERIS Initiative Opens a New Pathway for Breakthrough Defense Innovation

Leave a Comment / DARPA, Emerging Technologies / By

DARPA_ERIS_Announcement-_R9_1_April_2026 A New Front Door for Disruptive Defense Technology The Defense Advanced Research Projects Agency (DARPA), in partnership with its marketplace manager, the Applied Research Institute (ARI), has launched the Expedited Research Innovation System (ERIS), a long-term open call intended to accelerate the discovery and acquisition of novel technologies relevant to U.S. national security. DARPA

DARPA’s ERIS Initiative Opens a New Pathway for Breakthrough Defense Innovation Read More »

MCDC Host-Directed Therapeutics Initiative

MCDC’s Host-Directed Therapeutics Initiative

Leave a Comment / All Posts, CPE CBRND, Defense, Life Sciences / By

The Medical Chemical, Biological, Radiological, and Nuclear Defense Consortium (MCDC), managed by Advanced Technology International (ATI), has issued a Request for Information (RFI) focused on “Host-Directed Medical Countermeasures.” This effort, led in support of the Capability Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (CPE CBRND), represents an early step toward shaping a

MCDC’s Host-Directed Therapeutics Initiative Read More »

ARPA-H 1-CURE Initiative

ARPA-H’s 1-CURE Initiative to Revolutionize Universal Cancer Radiotherapy

Leave a Comment / All Posts, ARPA-H, Life Sciences / By

1-CURE_ISO_ARPA-H-SOL-26-147 Cancer remains one of the leading causes of death globally, with existing treatment modalities often limited by cost, accessibility, and effectiveness, particularly for metastatic disease. In response, the Advanced Research Projects Agency for Health (ARPA-H) has released an Innovative Solutions Opening (ISO) under solicitation ARPA-H-SOL-26-147 for the One Comprehensive Universal Radiotherapy for Everyone (1-CURE)

ARPA-H’s 1-CURE Initiative to Revolutionize Universal Cancer Radiotherapy Read More »

ARPA-H Delphi Program Draft Featured Image

ARPA-H’s Delphi Program Draft ISO Signals New Opportunities in Continuous Biosensing

Leave a Comment / All Posts, ARPA-H, Life Sciences / By

ARPA-H-SOL-26-153+DRAFT+Delphi+ISO Overview of the DELPHI Program The Advanced Research Projects Agency for Health (ARPA-H) has released a Draft Innovative Solutions Opening (ISO) for the Delphi program through its Resilient Systems Office (RSO). The draft announcement, ARPA-H-SOL-26-153, is intended to inform the research community about an upcoming funding opportunity and allow potential performers time to prepare

ARPA-H’s Delphi Program Draft ISO Signals New Opportunities in Continuous Biosensing Read More »

Scroll to Top